It is used for qualitative detection of IgG-class antibodies to Epstein-barr virus capsid antigen in human serum or plasma. It is intended to be used in clinical laboratories for diagnosis and management of patients related to infection with Epstein-barr virus. EBV infection can clinically lead to diseases such as X-linked lymphoid hyperplasia syndrome (XLPS), post-transplant lymphoproliferative disorder, nasopharyngeal carcinoma, Burkitt's lymphoma and infectious mononucleosis. A positive anti-shell antigen-IgM, negative anti-shell antigen-IgG and negative anti-EB nuclear antigen-IgG indicates a primary EBV infection; a positive anti-shell antigen-IgG and negative anti-EB nuclear antigen-IgG indicates a recent EBV infection; a positive anti-shell antigen-IgG and positive anti-EB nuclear antigen-IgG indicates a previous EBV infection. Nasopharyngeal Carcinoma is a malignant tumor that occurs in the mucosa of the nasopharynx and is associated with EBV infection, genetics, environment and diet. Clinical symptoms include aspiration, nasal congestion, tinnitus, hearing loss, and a sense of occlusion in the ear. Among the many EBV-related diseases, nasopharyngeal carcinoma is widely recognized for its high incidence and high risk.
